These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 33300437)
1. Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention. Zhang M; Wang J; Zhang Y; Zhang P; Chao Y; Gao M; Hou Y Perfusion; 2022 Jan; 37(1):78-85. PubMed ID: 33300437 [TBL] [Abstract][Full Text] [Related]
2. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI. Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236 [TBL] [Abstract][Full Text] [Related]
3. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients. Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750 [TBL] [Abstract][Full Text] [Related]
4. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials. Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752 [TBL] [Abstract][Full Text] [Related]
5. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
6. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598 [TBL] [Abstract][Full Text] [Related]
7. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH; Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581 [TBL] [Abstract][Full Text] [Related]
8. Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Xie X; Johnston SC; Wang A; Xu Q; Bath PM; Pan Y; Li H; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Xu A; Jing J; Meng X; Wang Y JAMA Netw Open; 2023 Jun; 6(6):e2317037. PubMed ID: 37279000 [TBL] [Abstract][Full Text] [Related]
9. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. Cavallari LH; Franchi F; Rollini F; Been L; Rivas A; Agarwal M; Smith DM; Newsom K; Gong Y; Elsey AR; Starostik P; Johnson JA; Angiolillo DJ J Transl Med; 2018 Apr; 16(1):92. PubMed ID: 29642909 [TBL] [Abstract][Full Text] [Related]
10. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854 [TBL] [Abstract][Full Text] [Related]
11. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
12. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. Jiang M; You JH Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625 [TBL] [Abstract][Full Text] [Related]
13. CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. Liu J; Nie XY; Zhang Y; Lu Y; Shi LW; Wang WM Chin Med J (Engl); 2015 Aug; 128(16):2183-8. PubMed ID: 26265611 [TBL] [Abstract][Full Text] [Related]
14. Risk of major adverse cardiovascular events of Biswas M; Kali MSK; Biswas TK; Ibrahim B Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772 [TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention. Lee SH; Jeong YH; Hong D; Choi KH; Lee JM; Park TK; Yang JH; Hahn JY; Choi SH; Gwon HC; Jeong MH; Kim BK; Joo HJ; Chang K; Park Y; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Song YB; JACC Cardiovasc Interv; 2023 Apr; 16(7):829-843. PubMed ID: 37045504 [TBL] [Abstract][Full Text] [Related]
17. Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention. Gao ST; Wang Y; Ma L Medicine (Baltimore); 2023 Sep; 102(37):e34974. PubMed ID: 37713840 [TBL] [Abstract][Full Text] [Related]
18. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117 [TBL] [Abstract][Full Text] [Related]
19. Effects of the Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400 [TBL] [Abstract][Full Text] [Related]